Dr. Fountzilas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm and Carlton St
Scott Bieler Clinical Science Center P-938
Buffalo, NY 14202Phone+1 716-845-1300Fax+1 716-845-8935
Summary
- Dr. Christos Fountzilas is an oncologist in Buffalo, NY and is affiliated with Roswell Park Comprehensive Cancer Center. He received his medical degree from Aristotle University of Thessaloniki School of Medicine and has been in practice 11 years. He speaks English and Greek. He specializes in gastrointestinal cancer and is experienced in esophageal cancer, cholangiocarcinoma, gastric cancer, colorectal cancer, and pancreatic cancer.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2013 - 2016
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 2010 - 2013
Aristotle University of Thessaloniki School of MedicineClass of 2006
Certifications & Licensure
NY State Medical License 2017 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Start of enrollment: 2021 Jun 08
Roles: Contact, Principal Investigator
- Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer Start of enrollment: 2024 Jan 15
Roles: Principal Investigator, Contact
- FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma Start of enrollment: 2024 Oct 01
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Design, synthesis and investigation of biological activity and mechanism of fluoroaryl-substituted derivatives at the FL118 position 7.Wenchao Wang, Ruojiong Wang, Lianhao An, Lei Li, Haonan Xiong
European Journal of Medicinal Chemistry. 2024-12-04 - Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.Erkut H Borazanci, Nathan Bahary, Vincent Chung, Timothy K Huyck, Ebenezer A Kio
The Oncologist. 2024-11-04 - 2 citationsDevimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: ...Philip A Philip, Vaibhav Sahai, Nathan Bahary, Amit Mahipal, Anup Kasi
Journal of Clinical Oncology. 2024-11-01
Press Mentions
NCCN Foundation Announces Awards for Rising Cancer Research LeadersApril 25th, 2022- Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual MeetingMay 16th, 2019
Chinese Tree Bark Being Used to Treat Pancreatic CancerMarch 15th, 2019- Join now to see all
Professional Memberships
- Fellow
- Member
- Member
Other Languages
- Greek
External Links
- Roswell Park Profilehttps://www.roswellpark.org/christos-fountzilas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
